Kilian Eyerich, MD, PhD

home / authors / killian-eyerich-md-phd

Articles

Upadacitinib Demonstrates Efficacy in Patients With AD and Head and Neck Involvement

Upadacitinib Demonstrates Efficacy in Patients With AD and Head and Neck Involvement

Emma Andrus, Associate Editor;Kilian Eyerich, MD, PhD;Kaitlyn Bader, Assistant Managing Editor
September 26th 2024

Kilian Eyerich, MD, PhD, shares insights into an EADV 2024 presentation on upadacitinib’s ability to achieve almost total skin clearance in the head and neck regions with minimal effect on quality of life.

Latest Updated Articles

2 KOLs are featured in this series.
Published: September 19th 2024 | Updated: September 26th 2024
Final Thoughts: The Importance of Comparative Studies in AD
POLL: “Lip Flips” or Lip Filler? Analyzing the Latest Trends in Lip Augmentation
Published: February 28th 2025 | Updated: May 8th 2025
POLL: “Lip Flips” or Lip Filler? Analyzing the Latest Trends in Lip Augmentation
CT-P39 is Just as Effective as Omalizumab for Chronic Spontaneous Urticaria Treatment
Published: January 23rd 2025 | Updated: May 8th 2025
CT-P39 is Just as Effective as Omalizumab for Chronic Spontaneous Urticaria Treatment
The Complex World of Urticaria: Insights from Jason Hawkes, MD, MS
Published: February 13th 2025 | Updated: May 8th 2025
The Complex World of Urticaria: Insights from Jason Hawkes, MD, MS
Q&A: Thomas Casale, MD, Discusses Abstract on Dupilumab and Significant Itch, Hive Reduction in Chronic Spontaneous Urticaria
Published: March 3rd 2025 | Updated: May 8th 2025
Q&A: Thomas Casale, MD, Discusses Abstract on Dupilumab and Significant Itch, Hive Reduction in Chronic Spontaneous Urticaria
Q&A: Jonathan Bernstein, MD, FAAAAI, Discusses Advances in Chronic Spontaneous Urticaria Treatments and AAAAI Data
Published: March 5th 2025 | Updated: May 8th 2025
Q&A: Jonathan Bernstein, MD, FAAAAI, Discusses Advances in Chronic Spontaneous Urticaria Treatments and AAAAI Data
© 2025 MJH Life Sciences

All rights reserved.